샘플 요청 목록

 카트 문의
시장보고서
상품코드
2148013

치료용 백신 시장

Therapeutic Vaccines
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 346 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,834,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 14,886,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,504,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 치료용 백신 시장은 2032년까지 602억 달러에 이를 전망

2025년에 263억 달러로 추정되는 세계의 치료용 백신 시장은 2025년부터 2032년까지 분석 기간 중 CAGR 12.6%로 성장하여 2032년까지 602억 달러에 이를 것으로 예상되고 있습니다. 본 보고서로 분석 대상이 되고 있는 부문 중 하나인 ' 자가면역질환용 백신 제품 '는 CAGR 12.7%를 나타내고, 분석 기간의 종료 시점까지 185억 달러에 이를 것으로 예상되고 있습니다.' 신경질환용 백신 제품 ' 부문의 성장 비율은 분석 기간 중 CAGR 14.4%로 추정되고 있습니다.

미국 시장은 72억 달러로 추계되는 한편, 중국은 CAGR 16.4%를 나타낼 것으로 예측됩니다

미국의 치료용 백신 시장은 2025년에 72억 달러로 추계되고 있습니다. 세계 제 2위 경제 규모를 자랑하는 중국은 2025년부터 2032년까지 분석 기간 중 CAGR 16.4%로 성장을 지속하여, 2032년까지 시장 규모가 128억 달러에 이를 것으로 예측됩니다. 기타 주목해야 할 지역 시장으로서는 일본과 캐나다를 들 수 있어 분석 기간 중에 각각 CAGR 9.5% 및 11.5%를 나타낼 것으로 예측됩니다. 유럽내에서는 독일이 CAGR 약 10.1%를 나타낼 것으로 예측됩니다.

세계의 치료용 백신 시장-주요 동향과 촉진요인의 개요

왜 치료용 백신이 이토록 주목을 받고 있는가?

면역계를 자극하여 질병과 싸우게 함으로써 기존 질환을 치료하도록 설계된 치료용 백신은 현대 의학의 초석이 되고 있습니다. 감염병 예방에 중점을 두는 기존 백신과 달리, 치료용 백신은 암, 만성 감염증, 자가면역질환 등 진행 중인 질환을 대상으로 합니다. 암 유병률 증가와 효과적인 치료 옵션으로서의 면역요법에 대한 관심 고조가 이 시장의 주요 촉진요인으로 작용하고 있습니다. 치료용 백신은 기존 치료법에 반응하지 않았던 환자의 치료에 혁명을 일으킬 가능성을 지니고 있어, 이로 인해 백신 시장 전체에서도 매우 역동적이고 빠르게 성장하고 있는 부문으로 자리매김하고 있습니다.

치료용 백신 시장의 각 부문은 어떻게 확대되고 있는가?

주목할 만한 부문으로는 HIV나 간염 등의 감염성 질환 및 자가면역 질환을 대상으로 하는 백신이 포함됩니다. 이러한 백신의 개발 과정에서 기술은 매우 중요한 역할을 하고 있으며, mRNA, 수지상 세포 기반 백신, 바이러스 벡터의 발전이 현저한 진전을 이끌고 있습니다. 최종 사용자 부문에는 주로 병원, 암 치료 센터, 연구 기관이 포함되며, 이들은 새로운 치료용 백신의 임상시험 및 초기 단계 연구를 수행하는 데 중요한 역할을 하고 있습니다.

시장을 형성하고 있는 기술적·규제적 동향은 무엇인가?

치료용 백신 시장은 생명공학 혁신, 특히 맞춤형 의료와 차세대 염기서열 분석의 부상에 큰 영향을 받고 있습니다. 면역 체계 및 종양 생물학에 대한 이해가 깊어짐에 따라 개별 환자에게 고도로 특화된 백신의 개발이 진행되고 있으며, 이는 시장 성장을 견인하고 있습니다. 또한, HPV 및 전립선암을 표적으로 하는 암 백신 등에 대한 규제 당국의 승인이 이 분야의 추가적인 혁신으로 가는 길을 열었습니다. 또 다른 중요한 동향으로는 백신 개발을 가속화하기 위해 제약 회사와 학술 연구 기관 간의 협력 관계가 깊어지고 있다는 점을 들 수 있습니다. 또한, 백신 연구를 지원하기 위한 정부의 이니셔티브와 자금 지원도 시장 성장을 위한 견고한 기반이 되고 있습니다.

치료용 백신 시장의 성장을 이끄는 주요 요인은 무엇일까요?

치료용 백신 시장의 성장은 암 및 만성 감염증 발생률 증가, 백신 개발 기술의 진보, 치료용 백신의 임상시험 건수 증가 등 여러 요인에 의해 주도되고 있습니다. 제약 기업의 연구 개발 투자 확대와 백신 제조 인프라 확충은 시장 성장의 중요한 원동력이 되고 있습니다. 또한, 면역 요법과 그 잠재적 이점에 대한 대중의 인식이 높아지면서 치료용 백신 수요가 증가하고 있습니다. 특정 치료용 백신에 대한 신속 승인이나 희귀질환 치료제 지정과 같은 규제상의 지원도 시장 확대에 기여하고 있습니다. 마지막으로, 보다 효과적인 암 치료를 추구하는 전 세계적인 흐름 속에서 특히 맞춤형 백신이 주목을 받으면서 이 시장의 현저한 성장을 뒷받침하고 있습니다.

부문:

제품(자가면역질환용 백신 제품, 신경질환용 백신 제품, 암용 백신 제품, 감염증용 백신 제품, 기타 제품), 기술(동종 이식 기술, 자가 이식 기술), 유통 채널(공적 유통 채널, 민간 유통 채널)

주요 기업

  • Agenus, Inc.
  • Bavarian Nordic A/S
  • CEL-SCI Corporation
  • Dendreon Corporation
  • GlaxoSmithKline PLC
  • Novartis International AG
  • Oncothyreon, Inc.
  • TVAX Biomedical Inc.
  • Vical, Inc.

각 분야의 전문가 관점을 바탕으로 합니다 - 산업계, 기업, 학계에 걸친 각 분야의 전문가로부터 얻은 관점을 반영하여, 기존에 공개된 조사 결과 이상의 맥락을 더하고 있습니다.

시장의 초기 신호를 포착합니다 - 기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다 - 컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업 공시 정보, 연차 보고서, 기관 간행물 및 기타 검증된 정보 출처에서 얻은 인사이트를 통합하고 있습니다.

신호와 전략적 시장 방향성을 연결합니다 - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있어 가장 중요할 가능성이 있는 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다 - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 관여하고 있는 기업을 상세하게 검토합니다.

주요 지역 시장 점유율을 면밀히 검토합니다 - 단일 세계 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구도는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서는 각 시장의 구조와 동향에 맞추어 상세도를 조정하여 주요 지역 시장 점유율 분석을 심층적으로 다룹니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

JHS 26.10.20

Global Therapeutic Vaccines Market to Reach US$60.2 Billion by 2032

The global market for Therapeutic Vaccines estimated at US$26.3 Billion in the year 2025, is expected to reach US$60.2 Billion by 2032, growing at a CAGR of 12.6% over the analysis period 2025-2032. Autoimmune Disease Vaccines Products, one of the segments analyzed in the report, is expected to record a 12.7% CAGR and reach US$18.5 Billion by the end of the analysis period. Growth in the Neurological Disease Vaccines Products segment is estimated at 14.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.2 Billion While China is Forecast to Grow at 16.4% CAGR

The Therapeutic Vaccines market in the U.S. is estimated at US$7.2 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$12.8 Billion by the year 2032 trailing a CAGR of 16.4% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.5% and 11.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Global Therapeutic Vaccines Market - Key Trends and Drivers Summarized

Why Are Therapeutic Vaccines Garnering So Much Attention?

Therapeutic vaccines, designed to treat existing diseases by stimulating the immune system to fight off illness, have become a cornerstone in modern medicine. Unlike traditional vaccines that focus on preventing infections, therapeutic vaccines target ongoing diseases such as cancer, chronic infections, and autoimmune disorders. The increasing prevalence of cancer and the growing interest in immunotherapy as a viable treatment option are key drivers in this market. Therapeutic vaccines hold the promise of revolutionizing treatment for patients who have not responded to conventional therapies, making this a highly dynamic and rapidly growing segment within the broader vaccine market.

How Are the Various Segments of the Therapeutic Vaccines Market Expanding?

Notable segments include vaccines targeting infectious diseases like HIV and hepatitis, as well as autoimmune disorders. Technology plays a crucial role in the development of these vaccines, with advances in mRNA, dendritic cell-based vaccines, and viral vectors driving significant progress. The end-user segments primarily include hospitals, cancer treatment centers, and research institutions, which are playing an instrumental role in conducting clinical trials and early-phase research on novel therapeutic vaccines.

What Technological and Regulatory Trends Are Shaping the Market?

The therapeutic vaccine market has been greatly influenced by innovations in biotechnology, particularly with the rise of personalized medicine and next-generation sequencing. Advances in understanding the immune system and tumor biology have led to the development of vaccines that are highly specific to individual patients, driving the market’s growth. Additionally, regulatory approvals for cancer vaccines, such as those targeting HPV and prostate cancer, have opened the door for further innovation in the field. Another key trend is the increasing collaboration between pharmaceutical companies and academic research institutes to accelerate vaccine development. Government initiatives and funding to support vaccine research are also providing a strong foundation for market growth.

What Are the Key Factors Driving Growth in the Therapeutic Vaccines Market?

The growth in the therapeutic vaccines market is driven by several factors, including the rising incidence of cancer and chronic infectious diseases, advancements in vaccine development technologies, and the growing number of clinical trials for therapeutic vaccines. Increased investments from pharmaceutical companies in R&D and the expansion of vaccine manufacturing infrastructure are critical drivers of market growth. Additionally, rising public awareness of immunotherapy and its potential benefits is fueling demand for therapeutic vaccines. Regulatory support in the form of fast-tracking approvals and orphan drug status for certain therapeutic vaccines is also contributing to market expansion. Finally, the global push for more effective cancer treatments is propelling significant growth in this market, especially as personalized vaccines gain traction.

SCOPE OF STUDY:

The report analyzes the Therapeutic Vaccines market by the following Segments, and Geographic Regions/Countries:

Segments:

Products (Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products, Other Productss); Technology (Allogeneic Technology, Autologous Technology); Distribution Channel (Public Distribution Channel, Private Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Agenus, Inc.
  • Bavarian Nordic A/S
  • CEL-SCI Corporation
  • Dendreon Corporation
  • GlaxoSmithKline PLC
  • Novartis International AG
  • Oncothyreon, Inc.
  • TVAX Biomedical Inc.
  • Vical, Inc.

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • Therapeutic Vaccines - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 13 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Cancer Immunotherapy Drives Demand for Therapeutic Vaccines
    • Increasing Number of Clinical Trials for Therapeutic Vaccines Expands Market Potential
    • Advances in mRNA Vaccine Technology Propel Growth in Therapeutic Vaccines
    • Growing Prevalence of Chronic Infectious Diseases Generates Demand for Therapeutic Vaccines
    • Increased Public Awareness of Preventative and Therapeutic Vaccines Spurs Demand
    • Development of Personalized Therapeutic Vaccines Expands Market Opportunities
    • Growing Use of Therapeutic Vaccines in Oncology Propels Market Expansion
    • Technological Advancements in Vaccine Delivery Systems Fuel Innovation in Therapeutic Vaccines
    • Rising Focus on Preventive Healthcare Strengthens the Business Case for Therapeutic Vaccines
    • Expansion of Vaccine Manufacturing Infrastructure Drives Market Demand
    • Increased Adoption of Therapeutic Vaccines in Developing Markets Expands Addressable Market
    • Global Vaccination Campaigns Against Emerging Diseases Propel Therapeutic Vaccine Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Therapeutic Vaccines Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for Therapeutic Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 3: World Historic Review for Therapeutic Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 4: World 13-Year Perspective for Therapeutic Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Autoimmune Disease Vaccines Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Autoimmune Disease Vaccines Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Autoimmune Disease Vaccines Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Neurological Disease Vaccines Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Neurological Disease Vaccines Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Neurological Disease Vaccines Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Cancer Vaccines Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Cancer Vaccines Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Cancer Vaccines Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Infectious Disease Vaccines Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Infectious Disease Vaccines Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Infectious Disease Vaccines Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Productss by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Other Productss by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Other Productss by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Allogeneic Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Allogeneic Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Allogeneic Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Autologous Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Autologous Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Autologous Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Public Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Public Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Public Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Private Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Private Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Private Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 33: USA Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: USA 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 35: USA Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 36: USA Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: USA 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 38: USA Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 39: USA Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: USA 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 42: Canada Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: Canada 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 45: Canada Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: Canada 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 48: Canada Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: Canada 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • JAPAN
    • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 51: Japan Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: Japan 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 54: Japan Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: Japan 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 57: Japan Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: Japan 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • CHINA
    • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 60: China Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: China 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 62: China Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 63: China Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: China 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 65: China Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 66: China Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: China 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • EUROPE
    • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Therapeutic Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 69: Europe Historic Review for Therapeutic Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: Europe 13-Year Perspective for Therapeutic Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: Europe Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: Europe 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 75: Europe Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: Europe 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 78: Europe Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: Europe 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • FRANCE
    • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 81: France Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: France 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 83: France Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: France Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: France 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 86: France Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: France Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: France 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • GERMANY
    • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: Germany Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: Germany 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: Germany Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: Germany 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 96: Germany Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: Germany 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Italy Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: Italy 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Italy Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Italy 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Italy Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: Italy 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 108: UK Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: UK 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 110: UK Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: UK Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: UK 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 113: UK Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: UK Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: UK 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: Spain Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: Spain 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: Spain Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: Spain 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: Spain Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: Spain 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: Russia Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: Russia 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Russia Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: Russia 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Russia Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Russia 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Rest of Europe 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Rest of Europe 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Rest of Europe 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Therapeutic Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Therapeutic Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: Asia-Pacific 13-Year Perspective for Therapeutic Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: Asia-Pacific 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: Asia-Pacific 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: Asia-Pacific 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 156: Australia Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: Australia 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Australia Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: Australia 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Australia Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: Australia 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • INDIA
    • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: India Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: India 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 167: India Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: India Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: India 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 170: India Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 171: India Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: India 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: South Korea Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: South Korea 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: South Korea Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: South Korea 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: South Korea Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: South Korea 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Therapeutic Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 192: Latin America Historic Review for Therapeutic Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: Latin America 13-Year Perspective for Therapeutic Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Latin America Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: Latin America 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 198: Latin America Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: Latin America 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 201: Latin America Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: Latin America 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Argentina Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: Argentina 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Argentina Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Argentina 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Argentina Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Argentina 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Brazil Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Brazil 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Brazil Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 217: Brazil 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Brazil Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 220: Brazil 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Mexico Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 223: Mexico 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Mexico Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 226: Mexico 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 228: Mexico Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 229: Mexico 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 232: Rest of Latin America 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 235: Rest of Latin America 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 238: Rest of Latin America 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Therapeutic Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 240: Middle East Historic Review for Therapeutic Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 241: Middle East 13-Year Perspective for Therapeutic Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 243: Middle East Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 244: Middle East 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 246: Middle East Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 247: Middle East 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 249: Middle East Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 250: Middle East 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Iran Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 253: Iran 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Iran Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 256: Iran 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Iran Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 259: Iran 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Israel Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 262: Israel 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Israel Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 265: Israel 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Israel Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 268: Israel 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 271: Saudi Arabia 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 274: Saudi Arabia 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 277: Saudi Arabia 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 279: UAE Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 280: UAE 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 282: UAE Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 283: UAE 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 285: UAE Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 286: UAE 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 289: Rest of Middle East 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 292: Rest of Middle East 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 295: Rest of Middle East 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032
  • AFRICA
    • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 297: Africa Historic Review for Therapeutic Vaccines by Products - Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 298: Africa 13-Year Perspective for Therapeutic Vaccines by Products - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines Products, Neurological Disease Vaccines Products, Cancer Vaccines Products, Infectious Disease Vaccines Products and Other Productss for the Years 2020, 2026 & 2032
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 300: Africa Historic Review for Therapeutic Vaccines by Technology - Allogeneic Technology and Autologous Technology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 301: Africa 13-Year Perspective for Therapeutic Vaccines by Technology - Percentage Breakdown of Value Sales for Allogeneic Technology and Autologous Technology for the Years 2020, 2026 & 2032
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 303: Africa Historic Review for Therapeutic Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 304: Africa 13-Year Perspective for Therapeutic Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기